Overview: Norovirus Antigen Rapid TestIntroduction: The Norovirus Antigen Rapid Test is a diagnostic tool designed to detect norovirus antigens in stool or saliva samples, facilitating the screening of norovirus infections. Caused by noroviruses, this highly contagious virus is a leading cause of gastroenteritis, presenting with vomiting, diarrhea, and severe complications like dehydration or electrolyte imbalance if untreated, particularly in closed settings like cruise ships or nursing homes. Per the 2023 Centers for Disease Control and Prevention guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with high sensitivity and specificity, making it a critical tool for rapid diagnosis during outbreaks. This rapid diagnostic falls under virology and targets individuals with acute gastrointestinal symptoms, addressing the challenge of identifying norovirus to guide supportive care and infection control measures like isolation. With morbidity rates elevated due to rapid transmission, the test supports public health efforts by enabling early detection, facilitating hygiene interventions, and reducing outbreak spread. Its dual-sample capability enhances its utility.Other Names: Norovirus Rapid Test.FDA Status: FDA approved, CLIA certified for virology, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Meridian Bioscience, this test advanced norovirus detection, providing a rapid alternative to electron microscopy.Purpose: The test screens for norovirus antigens to guide infection diagnosis, assess disease severity, and inform treatment and prevention strategies.Test Parameters: Presence of Norovirus Antigen, detected with high specificity to indicate active infection, typically detectable during the acute phase, peaking within 1-3 days of symptom onset.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report vomiting, diarrhea, or recent exposure to ill contacts.Specimen: Stool 5-10 gm, Saliva 1-2 mL, collected using sterile containers, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve antigen integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 48 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may denature antigens, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on vomiting, diarrhea, nausea, or recent exposure to norovirus outbreaks, as well as any immunosuppressive conditions.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated infection including dehydration, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or late infection after antigen clearance can affect results. Correlation with PCR or electron microscopy is recommended to confirm findings.Clinical Significance: A positive result indicates norovirus infection, necessitating supportive care and isolation. A negative result may require follow-up testing if symptoms persist, especially if sampled outside the antigen peak window.Specialist Consultation: Infectious disease specialists or gastroenterologists should be consulted for case management, treatment planning, and coordination with public health authorities.Additional Supporting Tests: Norovirus PCR, electron microscopy, or serology for confirmation.Test Limitations: The test may produce false negatives in late infection or false positives due to cross-reactivity, requiring a comprehensive diagnostic approach that includes molecular methods.References: CDC Guidelines 2023, Journal of Clinical Virology 2024, Gastroenterology 2025.